287 related articles for article (PubMed ID: 22512979)
1. Molecular pathways: old drugs define new pathways: non-histone acetylation at the crossroads of the DNA damage response and autophagy.
Botrugno OA; Robert T; Vanoli F; Foiani M; Minucci S
Clin Cancer Res; 2012 May; 18(9):2436-42. PubMed ID: 22512979
[TBL] [Abstract][Full Text] [Related]
2. Acetylation of proteins as novel target for antitumor therapy: review article.
Di Gennaro E; Bruzzese F; Caraglia M; Abruzzese A; Budillon A
Amino Acids; 2004 Jul; 26(4):435-41. PubMed ID: 15290351
[TBL] [Abstract][Full Text] [Related]
3. Deacetylation of nonhistone proteins by HDACs and the implications in cancer.
Peng L; Seto E
Handb Exp Pharmacol; 2011; 206():39-56. PubMed ID: 21879445
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitors in cancer therapy.
Lane AA; Chabner BA
J Clin Oncol; 2009 Nov; 27(32):5459-68. PubMed ID: 19826124
[TBL] [Abstract][Full Text] [Related]
5. [Assay for inhibitory activity of histone deacetylase].
Yoshida M
Gan To Kagaku Ryoho; 2004 Apr; 31(4):507-11. PubMed ID: 15114691
[TBL] [Abstract][Full Text] [Related]
6. HDACs link the DNA damage response, processing of double-strand breaks and autophagy.
Robert T; Vanoli F; Chiolo I; Shubassi G; Bernstein KA; Rothstein R; Botrugno OA; Parazzoli D; Oldani A; Minucci S; Foiani M
Nature; 2011 Mar; 471(7336):74-79. PubMed ID: 21368826
[TBL] [Abstract][Full Text] [Related]
7. Histone modification enzymes: novel targets for cancer drugs.
Kristeleit R; Stimson L; Workman P; Aherne W
Expert Opin Emerg Drugs; 2004 May; 9(1):135-54. PubMed ID: 15155140
[TBL] [Abstract][Full Text] [Related]
8. Targeting histone deacetylases: development of vorinostat for the treatment of cancer.
Richon VM
Epigenomics; 2010 Jun; 2(3):457-65. PubMed ID: 22121904
[TBL] [Abstract][Full Text] [Related]
9. Development of vorinostat: current applications and future perspectives for cancer therapy.
Richon VM; Garcia-Vargas J; Hardwick JS
Cancer Lett; 2009 Aug; 280(2):201-10. PubMed ID: 19181442
[TBL] [Abstract][Full Text] [Related]
10. Targeting protein acetylation for improving cancer therapy.
Dwarakanath BS; Verma A; Bhatt AN; Parmar VS; Raj HG
Indian J Med Res; 2008 Jul; 128(1):13-21. PubMed ID: 18820353
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of resistance to histone deacetylase inhibitors.
Lee JH; Choy ML; Marks PA
Adv Cancer Res; 2012; 116():39-86. PubMed ID: 23088868
[TBL] [Abstract][Full Text] [Related]
12. HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics.
Gallinari P; Di Marco S; Jones P; Pallaoro M; Steinkühler C
Cell Res; 2007 Mar; 17(3):195-211. PubMed ID: 17325692
[TBL] [Abstract][Full Text] [Related]
13. Protein deacetylases: enzymes with functional diversity as novel therapeutic targets.
Yoshida M; Shimazu T; Matsuyama A
Prog Cell Cycle Res; 2003; 5():269-78. PubMed ID: 14593721
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylases and cancer: causes and therapies.
Marks P; Rifkind RA; Richon VM; Breslow R; Miller T; Kelly WK
Nat Rev Cancer; 2001 Dec; 1(3):194-202. PubMed ID: 11902574
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
16. Anticancer activities of histone deacetylase inhibitors.
Bolden JE; Peart MJ; Johnstone RW
Nat Rev Drug Discov; 2006 Sep; 5(9):769-84. PubMed ID: 16955068
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of histone deacetylases: a new strategy to target epigenetic modifications for anticancer treatment.
Weidle UH; Grossmann A
Anticancer Res; 2000; 20(3A):1471-85. PubMed ID: 10928059
[TBL] [Abstract][Full Text] [Related]
18. HDAC inhibitors: clinical update and mechanism-based potential.
Glaser KB
Biochem Pharmacol; 2007 Sep; 74(5):659-71. PubMed ID: 17498667
[TBL] [Abstract][Full Text] [Related]
19. Sensitization of tumor cells by targeting histone deacetylases.
Perego P; Zuco V; Gatti L; Zunino F
Biochem Pharmacol; 2012 Apr; 83(8):987-94. PubMed ID: 22120677
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors in the treatment of lymphoma.
Lemoine M; Younes A
Discov Med; 2010 Nov; 10(54):462-70. PubMed ID: 21122478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
